AU2005311321A1 - G protein coupled receptor - Google Patents

G protein coupled receptor Download PDF

Info

Publication number: AU2005311321A1
Authority: AU; Australia
Prior art keywords: gpr39; seq; receptor; compound; protein
Prior art date: 2004-12-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2005311321A

Other languages

English (en)

Inventor

Bernard Coulie

Inge Irma Therese Depoortere

Diederik Willem Elisabeth Moechars

Benoit Christian Jean-Claude Moreaux

Theophiel Louis Henri Peeters

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-01

Filing date

2005-11-30

Publication date

2006-06-08

2005-11-30 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2006-06-08 Publication of AU2005311321A1 publication Critical patent/AU2005311321A1/en

Status Abandoned legal-status Critical Current

Links

102000003688 G-Protein-Coupled Receptors Human genes 0.000 title description 30
108090000045 G-Protein-Coupled Receptors Proteins 0.000 title description 30
101001009541 Homo sapiens G-protein coupled receptor 39 Proteins 0.000 claims description 180
102100030280 G-protein coupled receptor 39 Human genes 0.000 claims description 176
150000001875 compounds Chemical class 0.000 claims description 104
108090000765 processed proteins & peptides Proteins 0.000 claims description 86
238000000034 method Methods 0.000 claims description 84
102000004196 processed proteins & peptides Human genes 0.000 claims description 80
229920001184 polypeptide Polymers 0.000 claims description 78
150000007523 nucleic acids Chemical group 0.000 claims description 74
108020003175 receptors Proteins 0.000 claims description 57
102000005962 receptors Human genes 0.000 claims description 55
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 50
230000000694 effects Effects 0.000 claims description 44
230000002496 gastric effect Effects 0.000 claims description 37
230000027455 binding Effects 0.000 claims description 35
108090000623 proteins and genes Proteins 0.000 claims description 35
239000013598 vector Substances 0.000 claims description 34
238000003556 assay Methods 0.000 claims description 32
101800001586 Ghrelin Proteins 0.000 claims description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
230000001965 increasing effect Effects 0.000 claims description 28
230000030136 gastric emptying Effects 0.000 claims description 27
201000010099 disease Diseases 0.000 claims description 23
102000004169 proteins and genes Human genes 0.000 claims description 22
150000001413 amino acids Chemical group 0.000 claims description 21
OJSXICLEROKMBP-FFUDWAICSA-N 869705-22-6 Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OJSXICLEROKMBP-FFUDWAICSA-N 0.000 claims description 20
241001465754 Metazoa Species 0.000 claims description 19
101800000590 Obestatin Proteins 0.000 claims description 19
239000012634 fragment Substances 0.000 claims description 19
239000005557 antagonist Substances 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 17
239000012528 membrane Substances 0.000 claims description 17
206010021518 Impaired gastric emptying Diseases 0.000 claims description 15
108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 9
229940123084 GPR39 agonist Drugs 0.000 claims description 8
230000004600 colonic motility Effects 0.000 claims description 8
230000003834 intracellular effect Effects 0.000 claims description 8
230000004060 metabolic process Effects 0.000 claims description 8
239000011575 calcium Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
229910052791 calcium Inorganic materials 0.000 claims description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
108700008625 Reporter Genes Proteins 0.000 claims description 5
230000008859 change Effects 0.000 claims description 3
239000002464 receptor antagonist Substances 0.000 claims description 3
229940044551 receptor antagonist Drugs 0.000 claims description 3
229940044601 receptor agonist Drugs 0.000 claims description 2
239000000018 receptor agonist Substances 0.000 claims description 2
230000003111 delayed effect Effects 0.000 claims 2
102400000441 Obestatin Human genes 0.000 claims 1
210000004027 cell Anatomy 0.000 description 89
102000039446 nucleic acids Human genes 0.000 description 53
108020004707 nucleic acids Proteins 0.000 description 53
241000699670 Mus sp. Species 0.000 description 48
230000014509 gene expression Effects 0.000 description 30
102100033367 Appetite-regulating hormone Human genes 0.000 description 29
238000011813 knockout mouse model Methods 0.000 description 29
238000012360 testing method Methods 0.000 description 29
239000003446 ligand Substances 0.000 description 28
239000000203 mixture Substances 0.000 description 27
210000001519 tissue Anatomy 0.000 description 23
239000008188 pellet Substances 0.000 description 19
210000001072 colon Anatomy 0.000 description 17
108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
210000004379 membrane Anatomy 0.000 description 16
102000040430 polynucleotide Human genes 0.000 description 16
108091033319 polynucleotide Proteins 0.000 description 16
239000002157 polynucleotide Substances 0.000 description 16
239000000556 agonist Substances 0.000 description 15
230000004913 activation Effects 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
230000028327 secretion Effects 0.000 description 13
210000002784 stomach Anatomy 0.000 description 13
108020004459 Small interfering RNA Proteins 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 11
239000000243 solution Substances 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
230000000692 anti-sense effect Effects 0.000 description 10
230000007423 decrease Effects 0.000 description 10
238000009826 distribution Methods 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 10
238000005259 measurement Methods 0.000 description 10
238000000159 protein binding assay Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
239000007787 solid Substances 0.000 description 10
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 9
206010012735 Diarrhoea Diseases 0.000 description 9
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
229940095074 cyclic amp Drugs 0.000 description 9
230000037406 food intake Effects 0.000 description 9
235000012631 food intake Nutrition 0.000 description 9
230000006870 function Effects 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000007792 addition Methods 0.000 description 8
239000000872 buffer Substances 0.000 description 8
230000031154 cholesterol homeostasis Effects 0.000 description 8
206010012601 diabetes mellitus Diseases 0.000 description 8
235000013305 food Nutrition 0.000 description 8
208000001288 gastroparesis Diseases 0.000 description 8
235000012054 meals Nutrition 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
238000009472 formulation Methods 0.000 description 7
238000003753 real-time PCR Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
108090000994 Catalytic RNA Proteins 0.000 description 6
102000053642 Catalytic RNA Human genes 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
101150042601 Gpr39 gene Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
230000001186 cumulative effect Effects 0.000 description 6
238000001415 gene therapy Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000012346 open field test Methods 0.000 description 6
230000007170 pathology Effects 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
108091092562 ribozyme Proteins 0.000 description 6
238000012216 screening Methods 0.000 description 6
239000004055 small Interfering RNA Substances 0.000 description 6
208000024172 Cardiovascular disease Diseases 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
208000008279 Dumping Syndrome Diseases 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
208000001145 Metabolic Syndrome Diseases 0.000 description 5
208000032395 Post gastric surgery syndrome Diseases 0.000 description 5
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
239000000969 carrier Substances 0.000 description 5
239000001913 cellulose Chemical class 0.000 description 5
229920002678 cellulose Chemical class 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
230000002503 metabolic effect Effects 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000011734 sodium Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
102000030782 GTP binding Human genes 0.000 description 4
108091000058 GTP-Binding Proteins 0.000 description 4
206010018044 Gastroparesis postoperative Diseases 0.000 description 4
108010016122 Ghrelin Receptors Proteins 0.000 description 4
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000002860 competitive effect Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
201000006549 dyspepsia Diseases 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000009368 gene silencing by RNA Effects 0.000 description 4
208000008384 ileus Diseases 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
210000004897 n-terminal region Anatomy 0.000 description 4
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
230000000384 rearing effect Effects 0.000 description 4
210000000664 rectum Anatomy 0.000 description 4
230000010076 replication Effects 0.000 description 4
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229930024421 Adenine Natural products 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
108091006027 G proteins Proteins 0.000 description 3
102000000393 Ghrelin Receptors Human genes 0.000 description 3
241000282412 Homo Species 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
102100033818 Motilin receptor Human genes 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000007405 data analysis Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000029142 excretion Effects 0.000 description 3
238000000799 fluorescence microscopy Methods 0.000 description 3
230000004907 flux Effects 0.000 description 3
238000002825 functional assay Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
102000048420 human GPR39 Human genes 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000008991 intestinal motility Effects 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000036963 noncompetitive effect Effects 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
210000001187 pylorus Anatomy 0.000 description 3
238000003653 radioligand binding assay Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000000241 respiratory effect Effects 0.000 description 3
230000036387 respiratory rate Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
238000005070 sampling Methods 0.000 description 3
238000002821 scintillation proximity assay Methods 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
229940035044 sorbitan monolaurate Drugs 0.000 description 3
241000894007 species Species 0.000 description 3
238000010186 staining Methods 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
241000699694 Gerbillinae Species 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical class OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
102000017922 Neurotensin receptor Human genes 0.000 description 2
108060003370 Neurotensin receptor Proteins 0.000 description 2
102000016978 Orphan receptors Human genes 0.000 description 2
108070000031 Orphan receptors Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
108010080192 Purinergic Receptors Proteins 0.000 description 2
102000000033 Purinergic Receptors Human genes 0.000 description 2
108091027981 Response element Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
102000039471 Small Nuclear RNA Human genes 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
239000002253 acid Substances 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000000137 annealing Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000000338 anxiogenic effect Effects 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
238000004159 blood analysis Methods 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000019522 cellular metabolic process Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
208000035215 familial 3 autosomal dominant visceral neuropathy Diseases 0.000 description 2
-1 for example Substances 0.000 description 2
238000002873 global sequence alignment Methods 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000000703 high-speed centrifugation Methods 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000004068 intracellular signaling Effects 0.000 description 2
210000001630 jejunum Anatomy 0.000 description 2
238000005304 joining Methods 0.000 description 2
239000008101 lactose Chemical class 0.000 description 2
238000000670 ligand binding assay Methods 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000006179 pH buffering agent Substances 0.000 description 2
230000020477 pH reduction Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000007017 scission Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000001629 sign test Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229960004249 sodium acetate Drugs 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
239000008399 tap water Substances 0.000 description 2
235000020679 tap water Nutrition 0.000 description 2
WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
229940117013 triethanolamine oleate Drugs 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
208000019183 visceral myopathy Diseases 0.000 description 2
238000009736 wetting Methods 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
IXQREOREUIWJTJ-UHFFFAOYSA-N 2-amino-2-imino-1-phenylethanesulfonyl fluoride Chemical compound NC(=N)C(S(F)(=O)=O)C1=CC=CC=C1 IXQREOREUIWJTJ-UHFFFAOYSA-N 0.000 description 1
LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
101710111255 Appetite-regulating hormone Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091032955 Bacterial small RNA Proteins 0.000 description 1
VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
241000252983 Caecum Species 0.000 description 1
101000946068 Caenorhabditis elegans Ceramide glucosyltransferase 3 Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
101500025063 Canis lupus familiaris Obestatin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
108091033380 Coding strand Proteins 0.000 description 1
108010029704 Constitutive Androstane Receptor Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
DFCRUBKUVOJCOV-UHFFFAOYSA-N Fluo-5N Chemical compound OC(=O)CN(CC(O)=O)C1=CC=C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)C=C1OCCOC1=CC([N+]([O-])=O)=CC=C1N(CC(O)=O)CC(O)=O DFCRUBKUVOJCOV-UHFFFAOYSA-N 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
101100346768 Homo sapiens MLNR gene Proteins 0.000 description 1
101001132878 Homo sapiens Motilin receptor Proteins 0.000 description 1
101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
108700040483 Motilin receptors Proteins 0.000 description 1
101100069343 Mus musculus Gpr39 gene Proteins 0.000 description 1
101100508766 Mus musculus Impa2 gene Proteins 0.000 description 1
101100075442 Mus musculus Lrrc18 gene Proteins 0.000 description 1
101500025061 Mus musculus Obestatin Proteins 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102100033986 Neurotensin receptor type 1 Human genes 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
208000001649 Pica Diseases 0.000 description 1
108010039918 Polylysine Chemical group 0.000 description 1
206010054048 Postoperative ileus Diseases 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102000003661 Ribonuclease III Human genes 0.000 description 1
108010057163 Ribonuclease III Proteins 0.000 description 1
108091027967 Small hairpin RNA Proteins 0.000 description 1
206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
101500007311 Sus scrofa Obestatin Proteins 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
MCEXQZRGUKALLT-VVEOGCPPSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[[6-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-2-[(e)-(5-oxo-2-sulfanylideneimidazolidin-4-ylidene)methyl]-1-benzofuran-5-yl]oxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(\C=C\1C(NC(=S)N/1)=O)=C2 MCEXQZRGUKALLT-VVEOGCPPSA-N 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
229910052728 basic metal Inorganic materials 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000013262 cAMP assay Methods 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
210000002318 cardia Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000009956 central mechanism Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
229960004407 chorionic gonadotrophin Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000007865 diluting Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003596 drug target Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001278 effect on cholesterol Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000001842 enterocyte Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
238000003348 filter assay Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
231100000221 frame shift mutation induction Toxicity 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
230000030135 gastric motility Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
230000010243 gut motility Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
102000034345 heterotrimeric G proteins Human genes 0.000 description 1
108091006093 heterotrimeric G proteins Proteins 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
102000052301 human GNAZ Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
102000013988 human obestatin Human genes 0.000 description 1
108010011113 human obestatin Proteins 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
210000000091 mucous neck cell Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
238000010984 neurological examination Methods 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
108091008880 orphan GPCRs Proteins 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000036407 pain Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000009955 peripheral mechanism Effects 0.000 description 1
239000007793 ph indicator Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000656 polylysine Chemical group 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
239000011546 protein dye Substances 0.000 description 1
238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
108700003186 rat GPR39 Proteins 0.000 description 1
108010063336 rat obestatin Proteins 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
ZSOMPVKQDGLTOT-UHFFFAOYSA-J sodium green Chemical compound C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.COC=1C=C(NC(=O)C=2C=C(C(=CC=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C([O-])=O)C(OC)=CC=1N(CCOCC1)CCOCCOCCN1C(C(=C1)OC)=CC(OC)=C1NC(=O)C1=CC=C(C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C(C([O-])=O)=C1 ZSOMPVKQDGLTOT-UHFFFAOYSA-J 0.000 description 1
UGJCNRLBGKEGEH-UHFFFAOYSA-N sodium-binding benzofuran isophthalate Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O UGJCNRLBGKEGEH-UHFFFAOYSA-N 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
229960000874 thyrotropin Drugs 0.000 description 1
230000001748 thyrotropin Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229950009811 ubenimex Drugs 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2005311321A 2004-12-01 2005-11-30 G protein coupled receptor Abandoned AU2005311321A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04106220.9		2004-12-01
EP04106220		2004-12-01
PCT/EP2005/056350 WO2006058889A1 (en)	2004-12-01	2005-11-30	G protein coupled receptor

Publications (1)

Publication Number	Publication Date
AU2005311321A1 true AU2005311321A1 (en)	2006-06-08

Family

ID=34929976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2005311321A Abandoned AU2005311321A1 (en)	2004-12-01	2005-11-30	G protein coupled receptor

Country Status (10)

Country	Link
EP (1)	EP1820026A1 (ko)
JP (1)	JP2008521419A (ko)
KR (1)	KR20070086003A (ko)
CN (1)	CN101107529A (ko)
AU (1)	AU2005311321A1 (ko)
CA (1)	CA2587534A1 (ko)
NO (1)	NO20073294L (ko)
RU (1)	RU2007124609A (ko)
WO (1)	WO2006058889A1 (ko)
ZA (1)	ZA200704526B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1743944A4 (en) *	2004-04-23	2011-01-05	Takeda Pharmaceutical	NEW SCREENING PROCEDURE
JP2009539362A (ja) *	2006-06-08	2009-11-19	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｇタンパク質共役型受容体３９（ｇｐｒ３９）
CN111443209B (zh) *	2020-03-26	2022-12-20	中国中医科学院医学实验中心	一种筛选非激动剂型PPARγ配体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001257406A1 (en) *	2000-04-26	2001-11-07	Millennium Pharmaceuticals, Inc.	Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
US20020192711A1 (en) *	2001-04-20	2002-12-19	Nestor John J.	Methods for identifying ligands of G-Protein-Coupled receptors
US20030232769A1 (en) *	2002-06-17	2003-12-18	Isis Pharmaceuticals Inc.	Antisense modulation of G protein-coupled receptor 39 expression
JP2006513702A (ja) *	2002-09-09	2006-04-27	ヌラインコーポレーティッド	Ｇタンパク質共役受容体およびその使用
US20040071708A1 (en) *	2002-09-26	2004-04-15	Immusol, Inc.	GPR 39 modulators that control cancerous cell growth
CN1708589A (zh) *	2002-10-31	2005-12-14	詹森药业有限公司	Cns中crh应答基因
WO2004099782A2 (en) *	2003-05-05	2004-11-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)

2005
- 2005-11-30 EP EP05817427A patent/EP1820026A1/en not_active Withdrawn
- 2005-11-30 CN CNA2005800471189A patent/CN101107529A/zh active Pending
- 2005-11-30 CA CA002587534A patent/CA2587534A1/en not_active Abandoned
- 2005-11-30 KR KR1020077013092A patent/KR20070086003A/ko not_active Withdrawn
- 2005-11-30 AU AU2005311321A patent/AU2005311321A1/en not_active Abandoned
- 2005-11-30 WO PCT/EP2005/056350 patent/WO2006058889A1/en active Application Filing
- 2005-11-30 RU RU2007124609/15A patent/RU2007124609A/ru not_active Application Discontinuation
- 2005-11-30 JP JP2007543845A patent/JP2008521419A/ja active Pending
2007
- 2007-05-31 ZA ZA200704526A patent/ZA200704526B/xx unknown
- 2007-06-28 NO NO20073294A patent/NO20073294L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200704526B (en)	2008-11-26
WO2006058889A1 (en)	2006-06-08
JP2008521419A (ja)	2008-06-26
EP1820026A1 (en)	2007-08-22
RU2007124609A (ru)	2009-01-10
NO20073294L (no)	2007-08-29
CA2587534A1 (en)	2006-06-08
KR20070086003A (ko)	2007-08-27
CN101107529A (zh)	2008-01-16

Publication	Publication Date	Title
JP4619033B2 (ja)	2011-01-26	変異ｇｐｒ１０遺伝子を含むコンジェニックラット
JP2002520011A (ja)	2002-07-09	成長ホルモン分泌促進物質関連受容体および核酸
US20100168014A1 (en)	2010-07-01	Screening method
Nunoi et al.	2012	A relationship between motilin and growth hormone secretagogue receptors
US20030087799A1 (en)	2003-05-08	Modulation
US20070087388A1 (en)	2007-04-19	G protein coupled receptor
CA2652398A1 (en)	2007-12-13	G protein-coupled receptor 39 (gpr39)
AU2005311321A1 (en)	2006-06-08	G protein coupled receptor
KR100977824B1 (ko)	2010-08-25	Ｅｐｆ 수용체 에세이, 화합물 및 치료학적 조성물
EP1945661B1 (en)	2011-06-01	Gpr 146 receptor
HK1119234A (en)	2009-02-27	G protein coupled receptor
AU2001250410A1 (en)	2002-01-03	Adenine binding G protein coupled receptors
US20030096751A1 (en)	2003-05-22	G-protein coupled receptor polynucleotides and methods of use thereof
US20090048200A1 (en)	2009-02-19	GPR 26 G-Protein Coupled Receptor
WO2005121356A1 (ja)	2005-12-22	新規スクリーニング方法
JP2006290826A (ja)	2006-10-26	スクリーニング方法
MXPA96006544A (en)	1999-09-01	Receptors of melatonina of high affinity and susu
WO2006066599A2 (en)	2006-06-29	Mas related g protein coupled receptors as drug targets

Legal Events

Date	Code	Title	Description
2011-06-23	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application